Related Experiment Video
Updated: May 15, 2026

A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion
Published on: April 24, 2015
Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells
Dhong Hyo Kho1, Pratima Nangia-Makker, Vitaly Balan
1Departments of Oncology and Pathology, Wayne State University School of Medicine, Karmanos Cancer Institute, 110 E Warren Ave., Detroit, MI 48201, USA.
Abstract:
Trastuzumab (Herceptin) is an effective targeted therapy in HER2-overexpressing human breast carcinoma. However, many HER2-positive patients initially or eventually become resistant to this treatment, so elucidating mechanisms of trastuzumab resistance that emerge in breast carcinoma cells is clinically important. Here, we show that autocrine motility factor (AMF) binds to HER2 and induces cleavage to the ectodomain-deleted and constitutively active form p95HER2. Mechanistic investigations indicated that interaction of AMF with HER2 triggers HER2 phosphorylation and metalloprotease-mediated ectodomain shedding, activating phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase signaling and ablating the ability of trastuzumab to inhibit breast carcinoma cell growth. Furthermore, we found that HER2 expression and AMF secretion were inversely related in breast carcinoma cells. On the basis of this evidence that AMF may contribute to HER2-mediated breast cancer progression, our findings suggest that AMF-HER2 interaction might be a novel target for therapeutic management of patients with breast cancer, whose disease is resistant to trastuzumab.
Insights
Autocrine motility factor (AMF) binding to HER2 triggers resistance to trastuzumab in breast cancer. Targeting the AMF-HER2 interaction may overcome treatment resistance in HER2-positive patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Trastuzumab is a targeted therapy for HER2-overexpressing breast cancer.
- Resistance to trastuzumab is a significant clinical challenge in HER2-positive breast carcinoma patients.
- Understanding resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To elucidate the mechanisms by which breast carcinoma cells develop resistance to trastuzumab.
- To investigate the role of autocrine motility factor (AMF) in trastuzumab resistance.
- To identify potential novel therapeutic targets for overcoming trastuzumab resistance.
Main Methods:
- Investigated the interaction between AMF and HER2 in breast carcinoma cells.
- Analyzed HER2 phosphorylation and ectodomain shedding.
- Assessed the activation of phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling pathways.
- Examined the relationship between HER2 expression and AMF secretion.
Main Results:
- AMF binds to HER2, inducing cleavage to the active p95HER2 form.
- AMF interaction triggers HER2 phosphorylation and metalloprotease-mediated ectodomain shedding.
- This activation leads to PI3K and MAPK signaling, bypassing trastuzumab's inhibitory effects.
- An inverse relationship was observed between HER2 expression and AMF secretion in breast carcinoma cells.
Conclusions:
- AMF-HER2 interaction contributes to trastuzumab resistance in HER2-positive breast cancer.
- The AMF-HER2 pathway activates key signaling cascades that promote cancer cell growth despite trastuzumab treatment.
- Targeting the AMF-HER2 interaction presents a potential novel therapeutic strategy for managing trastuzumab-resistant breast cancer.
Related Concept Videos
Mitogens and the Cell Cycle
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Chemotaxis and Direction of Cell Migration

